Ribosomal frameshifting: an emerging drug target for HIV.
Combating HIV currently remains one of the key public health challenges. While immense effort has been invested in the development of HIV-targeted therapeutic agents, interfering with protein synthesis is a relatively unexplored area. HIV has an absolute requirement for a -1 ribosomal frameshift event during translation that constitutes a potentially attractive target for interfering with the viral life cycle. Research suggests that while a considerable amount of investigation is still required, targeting frameshifting in HIV with small molecules, peptides and oligonucleotides is feasible.
Gareiss
Peter C
PC
University of Rochester, Department of Dermatology, Rochester, New York, NY 14642, USA.
Miller
Benjamin L
BL
D019380:Anti-HIV Agents / Q000378:metabolism / Q000494:pharmacology*; D018965:Frameshifting, Ribosomal / Q000187:drug effects*; D015658:HIV Infections / Q000235:genetics; D015497:HIV-1 / Q000235:genetics / Q000378:metabolism; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000494:pharmacology*; D010455:Peptides / Q000235:genetics / Q000494:pharmacology*; D014176:Protein Biosynthesis / Q000187:drug effects; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism; D012270:Ribosomes / Q000378:metabolism*
D019380:Anti-HIV Agents; D016376:Oligonucleotides, Antisense; D010455:Peptides; D012367:RNA, Viral